Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 65 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Follow-Up Questions
Who is the CEO of Larimar Therapeutics Inc?
Dr. Carole Ben-Maimon is the President of Larimar Therapeutics Inc, joining the firm since 2020.
What is the price performance of LRMR stock?
The current price of LRMR is $4.41, it has increased 3.15% in the last trading day.
What are the primary business themes or industries for Larimar Therapeutics Inc?
Larimar Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Larimar Therapeutics Inc market cap?
Larimar Therapeutics Inc's current market cap is $377.8M
Is Larimar Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 13 analysts have made analyst ratings for Larimar Therapeutics Inc, including 9 strong buy, 8 buy, 1 hold, 0 sell, and 9 strong sell
